References
References Afonso, J., Ramirez-Campillo, R., Clemente, F. M., Büttner,
F. C., and Andrade, R. (2024). The Perils of Misinterpreting and
Misusing “Publication Bias” in Meta-analyses: An Education Review on
Funnel Plot-Based Methods. Sports Med 54, 257–269. doi:
10.1007/s40279-023-01927-9 Ahern, T. P., MacLehose, R. F., Haines, L.,
Cronin-Fenton, D. P., Damkier, P., Collin, L. J., et al. (2021).
Improving the transparency of meta-analyses with interactive web
applications. BMJ Evidence-Based Medicine 26, 327–332. doi:
10.1136/bmjebm-2019-111308 Behera, S., Catreux, S., Rossi, M., Truong,
S., Huang, Z., Ruehle, M., et al. (2025). Comprehensive genome analysis
and variant detection at scale using DRAGEN. Nat Biotechnol 43,
1177–1191. doi: 10.1038/s41587-024-02382-1 Bell, J. (2014). Stratified
medicines: towards better treatment for disease. The Lancet 383, S3–S5.
doi: 10.1016/S0140-6736(14)60115-X Bousman, C. A., Bengesser, S. A.,
Aitchison, K. J., Amare, A. T., Aschauer, H., Baune, B. T., et
al. (2020). Review and Consensus on Pharmacogenomic Testing in
Psychiatry. Pharmacopsychiatry 54, 5–17. doi: 10.1055/a-1288-1061
Bousman, C. A., Maruf, A. A., Marques, D. F., Brown, L. C., and Müller,
D. J. (2023a). The emergence, implementation, and future growth of
pharmacogenomics in psychiatry: a narrative review. Psychol Med 53,
7983–7993. doi: 10.1017/S0033291723002817 Bousman, C. A., Stevenson, J.
M., Ramsey, L. B., Sangkuhl, K., Hicks, J. K., Strawn, J. R., et
al. (2023b). Clinical Pharmacogenetics Implementation Consortium (CPIC)
Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and
Serotonin Reuptake Inhibitor Antidepressants. Clinical Pharmacology
& Therapeutics 114, 51–68. doi: 10.1002/cpt.2903 Brenner, M. H.,
Curbow, B., and Legro, M. W. (1995). The Proximal-Distal Continuum of
Multiple Health Outcome Measures: The Case of Cataract Surgery. Medical
Care 33, AS236–AS244. Champely, S. (2020). pwr: Basic Functions for
Power Analysis. Available at:
https://github.com/heliosdrm/pwr Chang, W., Cheng, J.,
Allaire, J. J., Sievert, C., Schloerke, B., Xie, Y., et al. (2025).
shiny: Web Application Framework for R. Available at:
https://shiny.posit.co/
Dellen, E. van (2024). Precision psychiatry: predicting predictability.
Psychological Medicine 54, 1500–1509. doi: 10.1017/S0033291724000370
Duarte, J. D., Thomas, C. D., Lee, C. R., Huddart, R., Agundez, J. A.
G., Baye, J. F., et al. (2024). Clinical Pharmacogenetics Implementation
Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and
GRK5 Genotypes and Beta-Blocker Therapy. Clinical Pharmacology &
Therapeutics 116, 939–947. doi: 10.1002/cpt.3351 Eichler, H.-G., Abadie,
E., Breckenridge, A., Flamion, B., Gustafsson, L. L., Leufkens, H., et
al. (2011). Bridging the efficacy–effectiveness gap: a regulator’s
perspective on addressing variability of drug response. Nat Rev Drug
Discov 10, 495–506. doi: 10.1038/nrd3501 Gelman, A., and Carlin, J.
(2014). Beyond Power Calculations: Assessing Type S (Sign) and Type M
(Magnitude) Errors. Perspect Psychol Sci 9, 641–651. doi:
10.1177/1745691614551642 Gottesman, I. I., and Gould, T. D. (2003). The
Endophenotype Concept in Psychiatry: Etymology and Strategic Intentions.
AJP 160, 636–645. doi: 10.1176/appi.ajp.160.4.636 Groenwold, R. H. H.
(2021). “Chapter 2 - The efficacy-effectiveness gap,” in Pragmatic
Randomized Clinical Trials, eds. C. J. Girman and M. E. Ritchey
(Academic Press), 9–19. doi: 10.1016/B978-0-12-817663-4.00024-6
Guchelaar, H.-J., van der Wouden, C. H., Manson, L. E. N.,
Abdullah-Koolmees, H., Blagec, K., Blagus, T., et al. (2025).
Pharmacogenetic Implementation Studies—Lessons Learned From the PREPARE
Study. Clin Pharmacol Ther. n/a. doi:
https://doi.org/10.1002/cpt.3749 Howes, O. D., Thase, M.
E., and Pillinger, T. (2022). Treatment resistance in psychiatry: state
of the art and new directions. Mol Psychiatry 27, 58–72. doi:
10.1038/s41380-021-01200-3 Huang, W., Percie du Sert, N., Vollert, J.,
and Rice, A. S. C. (2020). “General Principles of Preclinical Study
Design,” in Good Research Practice in Non-Clinical Pharmacology and
Biomedicine, eds. A. Bespalov, M. C. Michel, and T. Steckler (Cham:
Springer International Publishing), 55–69. doi: 10.1007/164_2019_277
Huda, A. S. (2019). The medical model in mental health: an explanation
and evaluation. Oxford: Oxford university press. Hughes, D. A. (2018).
Economics of Pharmacogenetic-Guided Treatments: Underwhelming or
Overstated? Clinical Pharmacology & Therapeutics 103, 749–751. doi:
10.1002/cpt.1030 Huhn, M., Tardy, M., Spineli, L. M., Kissling, W.,
Förstl, H., Pitschel-Walz, G., et al. (2014). Efficacy of
Pharmacotherapy and Psychotherapy for Adult Psychiatric Disorders: A
Systematic Overview of Meta-analyses. JAMA Psychiatry 71, 706–715. doi:
10.1001/jamapsychiatry.2014.112 Ingelman-Sundberg, M., and Molden, E.
(2025). Therapeutic drug monitoring, liquid biopsies or pharmacogenomics
for prediction of human drug metabolism and response. British Journal of
Clinical Pharmacology 91, 1569–1579. doi: 10.1111/bcp.16048 IntHout, J.,
Ioannidis, J. P. A., Rovers, M. M., and Goeman, J. J. (2016). Plea for
routinely presenting prediction intervals in meta-analysis. BMJ Open 6,
e010247. doi: 10.1136/bmjopen-2015-010247 Kacser, H., and Burns, J. A.
(1981). THE MOLECULAR BASIS OF DOMINANCE. Genetics 97, 639–666. doi:
10.1093/genetics/97.3-4.639 Klein, T. E., and Ritchie, M. D. (2018).
PharmCAT: A Pharmacogenomics Clinical Annotation Tool. Clinical
Pharmacology & Therapeutics 104, 19–22. doi: 10.1002/cpt.928
Lauschke, V. M., Zhou, Y., and Ingelman-Sundberg, M. (2024).
Pharmacogenomics Beyond Single Common Genetic Variants: The Way Forward.
Annual Review of Pharmacology and Toxicology 64, 33–51. doi:
10.1146/annurev-pharmtox-051921-091209 Leucht, S., Hierl, S., Kissling,
W., Dold, M., and Davis, J. M. (2012). Putting the efficacy of
psychiatric and general medicine medication into perspective: review of
meta-analyses. The British Journal of Psychiatry 200, 97–106. doi:
10.1192/bjp.bp.111.096594 Lüdecke, D. (2018). esc: Effect Size
Computation for Meta Analysis. doi: 10.5281/zenodo.1249218 Masimirembwa,
C., Dandara, C., and Hasler, J. (2014). “Chapter 43 - Population
Diversity and Pharmacogenomics in Africa,” in Handbook of
Pharmacogenomics and Stratified Medicine, ed. S. Padmanabhan (San Diego:
Academic Press), 971–998. doi: 10.1016/B978-0-12-386882-4.00043-8 Moher,
D., Liberati, A., Tetzlaff, J., and Altman, D. G. (2010). Preferred
reporting items for systematic reviews and meta-analyses: The PRISMA
statement. International Journal of Surgery 8, 336–341. doi:
10.1016/j.ijsu.2010.02.007 Nakagawa, S., Lagisz, M., O’Dea, R. E.,
Rutkowska, J., Yang, Y., Noble, D. W. A., et al. (2021). The orchard
plot: Cultivating a forest plot for use in ecology, evolution, and
beyond. Research Synthesis Methods 12, 4–12. doi: 10.1002/jrsm.1424
Nutt, D. J. (2025). Drug development in psychiatry: 50 years of failure
and how to resuscitate it. The Lancet Psychiatry 12, 228–238. doi:
10.1016/S2215-0366(24)00370-5 Pardiñas, A. F., Owen, M. J., and Walters,
J. T. R. (2021). Pharmacogenomics: A road ahead for precision medicine
in psychiatry. Neuron 109, 3914–3929. doi: 10.1016/j.neuron.2021.09.011
Pirmohamed, M., and Park, B. K. (2001). Genetic susceptibility to
adverse drug reactions. Trends in Pharmacological Sciences 22, 298–305.
doi: 10.1016/S0165-6147(00)01717-X PlotDigitizer: Version 3.1.6 (2025).
Available at:
https://plotdigitizer.com Popejoy, A. B. (2019).
Diversity In Precision Medicine And Pharmacogenetics: Methodological And
Conceptual Considerations For Broadening Participation
. PGPM 12, 257–271. doi: 10.2147/PGPM.S179742 Pustejovsky, J. (2024).
clubSandwich: Cluster-Robust (Sandwich) Variance Estimators with
Small-Sample Corrections. Available at: http://jepusto.github.io/clubSandwich/ R Core Team
(2021). R: A Language and Environment for Statistical Computing.
Available at: https://www.R-project.org/ Roden, D. M., Altman, R. B.,
Benowitz, N. L., Flockhart, D. A., Giacomini, K. M., Johnson, J. A., et
al. (2006). Pharmacogenomics: Challenges and Opportunities. Ann Intern
Med 145, 749–757. doi: 10.7326/0003-4819-145-10-200611210-00007 Roden,
D. M., McLeod, H. L., Relling, M. V., Williams, M. S., Mensah, G. A.,
Peterson, J. F., et al. (2019). Pharmacogenomics. The Lancet 394,
521–532. doi: 10.1016/S0140-6736(19)31276-0 Rodgers, M. A., and
Pustejovsky, J. E. (2021). Evaluating meta-analytic methods to detect
selective reporting in the presence of dependent effect sizes.
Psychological Methods 26, 141–160. doi: 10.1037/met0000300 Simon, N.,
and von Fabeck, K. (2025). Are plasma drug concentrations still
necessary? Rethinking the pharmacokinetic link in dose–response
relationships. Front. Pharmacol. 16. doi: 10.3389/fphar.2025.1660323
Sluis, S. van der, Verhage, M., Posthuma, D., and Dolan, C. V. (2010).
Phenotypic Complexity, Measurement Bias, and Poor Phenotypic Resolution
Contribute to the Missing Heritability Problem in Genetic Association
Studies. PLOS ONE 5, e13929. doi: 10.1371/journal.pone.0013929 Spina,
E., and de Leon, J. (2015). Clinical applications of CYP genotyping in
psychiatry. J Neural Transm 122, 5–28. doi: 10.1007/s00702-014-1300-5
Stern, S., Linker, S., Vadodaria, K. C., Marchetto, M. C., and Gage, F.
H. (2018). Prediction of response to drug therapy in psychiatric
disorders. Open Biology 8, 180031. doi: 10.1098/rsob.180031 van Zwet,
E., and Gelman, A. (2022). A Proposal for Informative Default Priors
Scaled by the Standard Error of Estimates. The American Statistician 76,
1–9. doi: 10.1080/00031305.2021.1938225 Viechtbauer, W. (2010).
Conducting Meta-Analyses in R with the metafor Package. Journal of
Statistical Software 36, 1–48. doi: 10.18637/jss.v036.i03 Wan, X., Wang,
W., Liu, J., and Tong, T. (2014). Estimating the sample mean and
standard deviation from the sample size, median, range and/or
interquartile range. BMC Medical Research Methodology 14, 135. doi:
10.1186/1471-2288-14-135 Whirl-Carrillo, M., Huddart, R., Gong, L.,
Sangkuhl, K., Thorn, C. F., Whaley, R., et al. (2021). An Evidence-Based
Framework for Evaluating Pharmacogenomics Knowledge for Personalized
Medicine. Clinical Pharmacology & Therapeutics 110, 563–572. doi:
10.1002/cpt.2350 Wu, A. H. B. (2015). Pharmacogenomic testing and
response to warfarin. The Lancet 385, 2231–2232. doi:
10.1016/S0140-6736(14)62219-4 Zhao, M., Ma, J., Li, M., Zhang, Y.,
Jiang, B., Zhao, X., et al. (2021). Cytochrome P450 Enzymes and Drug
Metabolism in Humans. International Journal of Molecular Sciences 22,
12808. doi: 10.3390/ijms222312808 Zöllner, S., and Pritchard, J. K.
(2007). Overcoming the Winner’s Curse: Estimating Penetrance Parameters
from Case-Control Data. The American Journal of Human Genetics 80,
605–615. doi: 10.1086/512821 Zwetsloot, P.-P., Van Der Naald, M., Sena,
E. S., Howells, D. W., IntHout, J., De Groot, J. A., et al. (2017).
Standardized mean differences cause funnel plot distortion in
publication bias assessments. eLife 6, e24260. doi:
10.7554/eLife.24260